Neurosteroids as novel antidepressants and anxiolytics: GABA-A receptors and beyond
The recent FDA approval of the neurosteroid, brexanolone (allopregnanolone), as a treatment for women with postpartum depression, and successful trials of a related neuroactive steroid, SGE-217, for men and women with major depressive disorder offer the hope of a new era in treating mood and anxiety...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-11-01
|
| Series: | Neurobiology of Stress |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352289519300487 |